Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02354261 · ClinicalTrials.gov registry record · Phase 2
Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
A Phase 2 study of Basal Cell Carcinoma in Basal Cell Nevus Syndrome, sponsored by HedgePath Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 5
- Study locations
NCT02354261: Completed Phase 2 study of Basal Cell Carcinoma in Basal Cell Nevus Syndrome, sponsored by HedgePath Pharmaceuticals.
NCT02354261 is a Phase 2 study of Basal Cell Carcinoma in Basal Cell Nevus Syndrome that has completed, run by HedgePath Pharmaceuticals. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02354261, a Phase 2 study of Basal Cell Carcinoma in Basal Cell Nevus Syndrome, has completed, sponsored by HedgePath Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 5
- Study locations
Study Summary
The study will assess the safety and efficacy of SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome.
Conditions Studied
Interventions
- DRUG SUBA-Itraconazole
Study Locations (5)
California
- Dermatology Specialists, Inc - Oceanside
Florida
- Ameriderm Research - Ormond Beach
Michigan
- Grekin Skin Institute - Warren
New York
- Stony Brook University - East Setauket
Pennsylvania
- Penn State Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2015-08-07 |
| Est. Completion | 2019-03 |
| Phase | Phase 2 |
What the finished NCT02354261 record still lists
NCT02354261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Basal Cell Carcinoma in Basal Cell Nevus Syndrome appearing as the primary indexed condition, and to 1 intervention - of which SUBA-Itraconazole is the first listed.
NCT02354261 lists 5 locations in 5 states (California, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT02354261 about?
NCT02354261 is a clinical study titled "Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)". The study will assess the safety and efficacy of SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome.
What is the current status of trial NCT02354261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2015-08-07. Estimated completion is 2019-03.
What conditions does trial NCT02354261 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma in Basal Cell Nevus Syndrome.
What interventions are being tested in trial NCT02354261?
The interventions under investigation include: SUBA-Itraconazole (DRUG).
Who is sponsoring clinical trial NCT02354261?
This trial is sponsored by HedgePath Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02354261 being conducted?
This trial has 5 study locations across California, Florida, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02354261's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI